enGene, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Public, Subsidiary
- Established
- 1999-01-01
- Employees
- 51
- Market Cap
- -
- Website
- https://www.engene.com
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Phase 1
Recruiting
- Conditions
- Superficial Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Interventions
- Drug: EG-70 (phase 1)Drug: EG-70 (phase 2)
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- enGene, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT04752722
- Locations
- 🇪🇸
Hospital Clinic Barcelona, Barcelona, Spain
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Colorado Clinical Research, Lakewood, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath